Biolex Therapeutics Commences Phase 2B Trial of Locteron® in Chronic Hepatitis C
Biolex Therapeutics, Inc. announced today the commencement of patient dosing in the SELECT-2 Phase 2b trial of its lead product candidate Locteron for the treatment of chronic hepatitis C. Locteron, controlled-release interferon alpha 2b, is designed to im... [more]
